Literature DB >> 21969570

Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer.

Earl Gillespie1, Susan E Leeman, Luisa A Watts, Jennifer A Coukos, Michael J O'Brien, Sandra R Cerda, Francis A Farraye, Arthur F Stucchi, James M Becker.   

Abstract

Patients with chronic ulcerative colitis (UC) are at high risk for developing colorectal cancer. In this study, archival formalin-fixed paraffin-embedded colonic tissue from patients with UC who developed carcinoma (CA) or high-grade dysplasia (HGD) was examined for changes in expression of the proinflammatory and mitogenic neurokinin-1 receptor (NK-1R). Laser capture microscopy was used to microdissect epithelia from areas of colons that showed histologic evidence of CA, HGD, and epithelia that were not dysplastic or cancerous but did contain evidence of prior inflammation (quiescent colitis). mRNA was extracted from the dissected tissue, and PCR array analysis was performed on extracted mRNA. Two antibodies were necessary to separately estimate the protein levels of the truncated (tr-NK-1R) and full-length (fl-NK-1R) receptors by immunohistochemistry. mRNA expression of tr-NK-1R increased 14-fold (P = 0.02) when comparing the HGD and CA groups. In contrast, the fl-NK-1R transcript showed no significant differences among groups. The protein levels of the total NK-1R increased by 40% (P = 0.02) in HGD and 80% (P = 0.0007) in CA compared with quiescent colitis. There were no significant changes in protein levels of the fl-NK-1R. We conclude that the increase in total NK-1R protein in HGD and CA is attributable to an increase in tr-NK-1R, suggesting there may be a functional role for tr-NK-1R in malignant transformation in colitis-associated cancer. The tr-NK-1R could prove useful as a diagnostic marker to identify patients at risk for neoplasia and may serve as a useful therapeutic target in the treatment of colitis-associated cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969570      PMCID: PMC3198340          DOI: 10.1073/pnas.1114275108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity.

Authors:  Eoin P Cummins; Edurne Berra; Katrina M Comerford; Amandine Ginouves; Kathleen T Fitzgerald; Fergal Seeballuck; Catherine Godson; Jens E Nielsen; Paul Moynagh; Jacques Pouyssegur; Cormac T Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-17       Impact factor: 11.205

2.  An unidentified depressor substance in certain tissue extracts.

Authors:  U S V Euler; J H Gaddum
Journal:  J Physiol       Date:  1931-06-06       Impact factor: 5.182

3.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Nuclear factor-kappaB is central to the expression of truncated neurokinin-1 receptor in breast cancer: implication for breast cancer cell quiescence within bone marrow stroma.

Authors:  Shakti H Ramkissoon; Prem S Patel; Marcelo Taborga; Pranela Rameshwar
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

5.  Effect of a neurokinin-1 receptor antagonist in a rat model of colitis-associated colon cancer.

Authors:  Beatriz Pagán; Angel A Isidro; Domenico Coppola; Zhengming Chen; Yuan Ren; Jie Wu; Caroline B Appleyard
Journal:  Anticancer Res       Date:  2010-09       Impact factor: 2.480

6.  Protein kinase C-mediated desensitization of the neurokinin 1 receptor.

Authors:  O Déry; K A Defea; N W Bunnett
Journal:  Am J Physiol Cell Physiol       Date:  2001-05       Impact factor: 4.249

7.  The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines.

Authors:  Marisa Rosso; María Jose Robles-Frías; Rafael Coveñas; Manuel Vicente Salinas-Martín; Miguel Muñoz
Journal:  Tumour Biol       Date:  2008-09-09

8.  Substance P receptor expression in intestinal epithelium in clostridium difficile toxin A enteritis in rats.

Authors:  C Pothoulakis; I Castagliuolo; S E Leeman; C C Wang; H Li; B J Hoffman; E Mezey
Journal:  Am J Physiol       Date:  1998-07

9.  NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.

Authors:  Miguel Muñoz; Marisa Rosso; Francisco J Aguilar; Miguel A González-Moles; Maximino Redondo; Francisco Esteban
Journal:  Invest New Drugs       Date:  2007-09-29       Impact factor: 3.850

10.  Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa.

Authors:  G Rogler; K Brand; D Vogl; S Page; R Hofmeister; T Andus; R Knuechel; P A Baeuerle; J Schölmerich; V Gross
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

View more
  22 in total

Review 1.  Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.

Authors:  Martin S Steinhoff; Bengt von Mentzer; Pierangelo Geppetti; Charalabos Pothoulakis; Nigel W Bunnett
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

Review 2.  Involvement of substance P and the NK-1 receptor in pancreatic cancer.

Authors:  Miguel Muñoz; Rafael Coveñas
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

3.  Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia.

Authors:  Raymond A Isidro; Myrella L Cruz; Angel A Isidro; Axel Baez; Axel Arroyo; William A González-Marqués; Carmen González-Keelan; Esther A Torres; Caroline B Appleyard
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 4.  Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis.

Authors:  Susmit Suvas
Journal:  J Immunol       Date:  2017-09-01       Impact factor: 5.422

5.  Truncated neurokinin-1 receptor is an ubiquitous antitumor target in hepatoblastoma, and its expression is independent of tumor biology and stage.

Authors:  Agnès Garnier; Matthias Ilmer; Kristina Becker; Beate Häberle; Dietrich VON Schweinitz; Roland Kappler; Michael Berger
Journal:  Oncol Lett       Date:  2015-11-20       Impact factor: 2.967

6.  Difference in expression of two neurokinin-1 receptors in adenoma and carcinoma from patients that underwent radical surgery for colorectal carcinoma.

Authors:  Xia Gao; Zhenjun Wang
Journal:  Oncol Lett       Date:  2017-07-15       Impact factor: 2.967

Review 7.  The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.

Authors:  Miguel Munoz; Rafael Covenas; Francisco Esteban; Maximino Redondo
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

8.  Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.

Authors:  A Molinos-Quintana; P Trujillo-Hacha; J I Piruat; J A Bejarano-García; E García-Guerrero; J A Pérez-Simón; Miguel Muñoz
Journal:  Invest New Drugs       Date:  2018-05-02       Impact factor: 3.850

Review 9.  Alternative Splicing of G Protein-Coupled Receptors: Relevance to Pain Management.

Authors:  Folabomi A Oladosu; William Maixner; Andrea G Nackley
Journal:  Mayo Clin Proc       Date:  2015-08       Impact factor: 7.616

10.  An indirect role for oncomir-519b in the expression of truncated neurokinin-1 in breast cancer cells.

Authors:  Peter Navarro; Shakti H Ramkissoon; Simant Shah; Jacqueline M Park; Raghav G Murthy; Shyam A Patel; Steven J Greco; Pranela Rameshwar
Journal:  Exp Cell Res       Date:  2012-09-12       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.